CAL
DMAC icon

Capital Analysts LLC’s DiaMedica Therapeutics DMAC Stock Holding History

Capital Analysts LLC’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Hold
1,050
– – ﹤0.01% 1342
2026
Q1 		$7K Hold
1,050
– – ﹤0.01% 1311
2025
Q4 		$8K Buy
+1,050
New +$7.85K ﹤0.01% 1269

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital Analysts LLC's DMAC Position: Q2 2026 in Review

Capital Analysts LLC held its DiaMedica Therapeutics (DMAC) position steady in Q2 2026 at 1,050 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #1342.

Capital Analysts LLC first reported a position in DMAC in Q4 2025 and has held it in 3 quarters since. The position peaked at $8K in Q4 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Capital Analysts LLC held 1,050 shares of DiaMedica Therapeutics worth $7K as of Q2 2026.
  • Capital Analysts LLC left its DiaMedica Therapeutics share count unchanged in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Capital Analysts LLC's portfolio in Q2 2026, its #1342 holding.
  • Capital Analysts LLC first reported a position in DiaMedica Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Capital Analysts LLC's DiaMedica Therapeutics position peaked at $8K in Q4 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.